179 related articles for article (PubMed ID: 36827041)
1. Novel diagnostic biomarkers of T cell-mediated tumor killing characteristics for early-stage triple negative breast cancer: A SEER analysis and molecular portraits.
Chang Q; Fan L; Li M; Liu L
Medicine (Baltimore); 2023 Feb; 102(8):e33059. PubMed ID: 36827041
[TBL] [Abstract][Full Text] [Related]
2. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer.
Li X; Yang J; Peng L; Sahin AA; Huo L; Ward KC; O'Regan R; Torres MA; Meisel JL
Breast Cancer Res Treat; 2017 Jan; 161(2):279-287. PubMed ID: 27888421
[TBL] [Abstract][Full Text] [Related]
3. Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis.
He X; Ji J; Dong R; Liu H; Dai X; Wang C; Esteva FJ; Yeung SJ
Breast Cancer Res Treat; 2019 Jan; 173(2):329-341. PubMed ID: 30341462
[TBL] [Abstract][Full Text] [Related]
4. Prognosis in triple-negative apocrine carcinomas of the breast: A population-based study.
Wu W; Wu M; Peng G; Shi D; Zhang J
Cancer Med; 2019 Dec; 8(18):7523-7531. PubMed ID: 31642210
[TBL] [Abstract][Full Text] [Related]
5. Influence of advanced age on the prognosis of triple-negative breast cancer patients: A surveillance, epidemiology, and end results-based study.
Tan H; Fu D
J Cancer Res Ther; 2023 Apr; 19(Supplement):S0. PubMed ID: 37147967
[TBL] [Abstract][Full Text] [Related]
6. Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study.
Schreiber AR; Kagihara J; Eguchi M; Kabos P; Fisher CM; Meyer E; Molina E; Kondapalli L; Bradley CJ; Diamond JR
Breast Cancer Res Treat; 2022 Jan; 191(2):389-399. PubMed ID: 34705147
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of male triple negative breast cancer: A population-based study.
Ghani S; Sochat M; Luo J; Tao Y; Ademuyiwa F
Breast J; 2020 Sep; 26(9):1748-1755. PubMed ID: 32856383
[TBL] [Abstract][Full Text] [Related]
8. Major cardiovascular adverse events in older adults with early-stage triple-negative breast cancer treated with adjuvant taxane + anthracycline versus taxane-based chemotherapy regimens: A SEER-medicare study.
Roy S; Lakritz S; Schreiber AR; Kuna EM; Bradley CJ; Kondapalli L; Diamond JR
Eur J Cancer; 2024 Jan; 196():113426. PubMed ID: 38000217
[TBL] [Abstract][Full Text] [Related]
9. Similar outcomes between adenoid cystic carcinoma of the breast and invasive ductal carcinoma: a population-based study from the SEER 18 database.
Chen QX; Li JJ; Wang XX; Lin PY; Zhang J; Song CG; Shao ZM
Oncotarget; 2017 Jan; 8(4):6206-6215. PubMed ID: 28008158
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages?
Agarwal G; Nanda G; Lal P; Mishra A; Agarwal A; Agrawal V; Krishnani N
World J Surg; 2016 Jun; 40(6):1362-72. PubMed ID: 26842691
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Adjuvant Treatments for T1 N0 M0 Triple-Negative Breast Cancer.
Zhai Z; Zheng Y; Yao J; Liu Y; Ruan J; Deng Y; Zhou L; Zhao P; Yang S; Hu J; We B; Wu Y; Zhang D; Kang H; Dai Z
JAMA Netw Open; 2020 Nov; 3(11):e2021881. PubMed ID: 33211105
[TBL] [Abstract][Full Text] [Related]
12. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
[TBL] [Abstract][Full Text] [Related]
13. Upregulated cyclins may be novel genes for triple-negative breast cancer based on bioinformatic analysis.
Lu Y; Yang G; Xiao Y; Zhang T; Su F; Chang R; Ling X; Bai Y
Breast Cancer; 2020 Sep; 27(5):903-911. PubMed ID: 32338339
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for distant metastasis of patients with primary triple-negative breast cancer.
Yao Y; Chu Y; Xu B; Hu Q; Song Q
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31113872
[No Abstract] [Full Text] [Related]
15. Opportunities for improving triple-negative breast cancer outcomes: results of a population-based study.
Rapiti E; Pinaud K; Chappuis PO; Viassolo V; Ayme A; Neyroud-Caspar I; Usel M; Bouchardy C
Cancer Med; 2017 Mar; 6(3):526-536. PubMed ID: 28211614
[TBL] [Abstract][Full Text] [Related]
16. The different outcomes between breast-conserving surgery and mastectomy in triple-negative breast cancer: a population-based study from the SEER 18 database.
Chen QX; Wang XX; Lin PY; Zhang J; Li JJ; Song CG; Shao ZM
Oncotarget; 2017 Jan; 8(3):4773-4780. PubMed ID: 27999201
[TBL] [Abstract][Full Text] [Related]
17. Regulator of G protein signaling 20 correlates with clinicopathological features and prognosis in triple-negative breast cancer.
Li Q; Jin W; Cai Y; Yang F; Chen E; Ye D; Wang Q; Guan X
Biochem Biophys Res Commun; 2017 Apr; 485(3):693-697. PubMed ID: 28237701
[TBL] [Abstract][Full Text] [Related]
18. Radiotherapy after surgery has significant survival benefits for patients with triple-negative breast cancer.
Yao Y; Chu Y; Xu B; Hu Q; Song Q
Cancer Med; 2019 Feb; 8(2):554-563. PubMed ID: 30632300
[TBL] [Abstract][Full Text] [Related]
19. High expression of TLR3 in triple-negative breast cancer predicts better prognosis-data from the Fudan University Shanghai Cancer Center cohort and tissue microarrays.
Fan L; Sui XY; Jin X; Zhang WJ; Zhou P; Shao ZM
BMC Cancer; 2023 Apr; 23(1):298. PubMed ID: 37005579
[TBL] [Abstract][Full Text] [Related]
20. Novel biomarkers identified in triple-negative breast cancer through RNA-sequencing.
Chen YL; Wang K; Xie F; Zhuo ZL; Liu C; Yang Y; Wang S; Zhao XT
Clin Chim Acta; 2022 Jun; 531():302-308. PubMed ID: 35504321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
